References
- Nissen SE, Lincroft AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388:1353–1364.
- Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2023. doi: 10.1001/jama.2023.9696
- World Health Organization. Cardiovascular diseases. https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1 [Last accessed 21 Jun 2023]
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082–e1143.
- Pinkosky SL, Newton RS, Day RS, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreased LDL-C and attenuates atherosclerosis. Nat Commun. 2016;13:13457.
- Ballantyne CM, Davidson MH, MacDougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62(13):1154–1162. doi: 10.1016/j.jacc.2013.05.050
- Gutierrez M, Rosenberg NL, MacDougall DE, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34:676–683. doi: 10.1161/ATVBAHA.113.302677
- Thompson PD, Rubino J, Janik MJ, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipid. 2015;9(3):295–304. doi: 10.1016/j.jacl.2015.03.003
- Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–1032. doi: 10.1056/NEJMoa1803917
- Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins of low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019;322:1780–1788. doi: 10.1001/jama.2019.16585
- Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions. A systematic review and meta-analysis. JAMA. 2016;315:1289–1297. doi: 10.1001/jama.2016.13985
- Fischer S, Julius U. Management of patients with statin intolerance. Atheroscler Suppl. 2017;30:33–37. doi: 10.1016/j.atherosclerosissup.2017.05.013
- Jadhav SB, Crass RL, Chapel S, et al. Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model. Eur Heart J Cardiovasc Pharmacother. 2022;8:578–586. doi: 10.1093/ehjcvp/pvab064
- Ballantyne CM, Laufs U, Ray K, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27(6):593–603. doi: 10.1177/2047487319864671
- Bays HE, Baum SJ, Brinton EA, et al. Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. Am J Prev Cardiol. 2021;8:200278.
- McQueen RB, Baum SJ, Louie MJ, et al. Potential cardiovascular events avoided with bempedoic acid plus ezetimibe fixed-dose combination compared with ezetimibe alone in patients with atherosclerotic cardiovascular disease taking maximally tolerate statins. Am J Cardiovasc Drugs. 2023;23:67–76. doi: 10.1007/s40256-022-00552-7